Trade Revance The - RVNC CFD
Add to favourite- Summary
- Historical Data
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.64 |
Open | 3.61 |
1-Year Change | -88.76% |
Day's Range | 3.52 - 3.69 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 24, 2024 | 3.55 | -0.06 | -1.66% | 3.61 | 3.72 | 3.51 |
Apr 23, 2024 | 3.64 | 0.02 | 0.55% | 3.62 | 3.78 | 3.59 |
Apr 22, 2024 | 3.62 | -0.16 | -4.23% | 3.78 | 3.80 | 3.59 |
Apr 19, 2024 | 3.75 | 0.01 | 0.27% | 3.74 | 3.84 | 3.69 |
Apr 18, 2024 | 3.77 | 0.08 | 2.17% | 3.69 | 3.79 | 3.60 |
Apr 17, 2024 | 3.72 | -0.10 | -2.62% | 3.82 | 3.87 | 3.72 |
Apr 16, 2024 | 3.79 | -0.10 | -2.57% | 3.89 | 3.90 | 3.70 |
Apr 15, 2024 | 3.95 | -0.10 | -2.47% | 4.05 | 4.16 | 3.94 |
Apr 12, 2024 | 4.11 | -0.22 | -5.08% | 4.33 | 4.38 | 4.08 |
Apr 11, 2024 | 4.42 | 0.02 | 0.45% | 4.40 | 4.48 | 4.19 |
Apr 10, 2024 | 4.38 | -0.03 | -0.68% | 4.41 | 4.46 | 4.29 |
Apr 9, 2024 | 4.67 | 0.22 | 4.94% | 4.45 | 4.91 | 4.44 |
Apr 8, 2024 | 4.43 | 0.10 | 2.31% | 4.33 | 4.44 | 4.33 |
Apr 5, 2024 | 4.38 | 0.04 | 0.92% | 4.34 | 4.44 | 4.30 |
Apr 4, 2024 | 4.38 | -0.24 | -5.19% | 4.62 | 4.64 | 4.33 |
Apr 3, 2024 | 4.52 | 0.02 | 0.44% | 4.50 | 4.61 | 4.34 |
Apr 2, 2024 | 4.48 | -0.10 | -2.18% | 4.58 | 4.58 | 4.42 |
Apr 1, 2024 | 4.71 | -0.22 | -4.46% | 4.93 | 4.93 | 4.64 |
Mar 28, 2024 | 4.88 | -0.01 | -0.20% | 4.89 | 4.98 | 4.83 |
Mar 27, 2024 | 4.91 | 0.20 | 4.25% | 4.71 | 4.93 | 4.65 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Revance The Company profile
About Revance Therapeutics Inc
Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Revance Therapeutics Inc revenues increased from $15.3M to $77.8M. Net loss increased less than 1% to $281.3M. Revenues reflect Product Segment increase from $14.9M to $76.5M, Service Segment increase from $417K to $1.3M. Net loss reflects Research & Development balance decrease of 11% to $99.4M (expense), Interest expense decrease of 59% to $6.3M (expense).
Industry: | Biopharmaceuticals |
1222 Demonbreun Street
Suite 2000
NASHVILLE
TENNESSEE 37203
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com